JPEN, Journal of Parenteral and Enteral Nutrition 2005: Vol 29 Index

2005·1.1 MB·English

Subject and Author Index to Volume 29
Abstracts, from Nutrition Week 2005, S1 (Jan—Feb) DeltaTrac, energy expenditure measurements by MedGem versus, 212
Alanyl-glutamine, in PN, 262 Diabetes mellitus type 2, glycemic and lipid control, EN and, 21
Allergic reaction, PN-associated urticaria and, 451 Diaphragm muscle, function of, alanyl-glutamine use in cecal ligation and
Amino acids, colon protein synthesis and, 255 puncture-induced sepsis and, 36
Anorexia nervosa, body mass index and bioimpedance and anthropometry Diarrhea, in severely burned children, 8
estimates of body compartments in, 148 Diet, high-fiber, hepatocyte apoptosis, liver regeneration after partial hepatec-
Anthropometry, body mass index in anorexia nervosa and, 148 tomy and, 401
Apoptosis, of intestinal cells after small-bowel resection, leptin and, 30 Dietary restriction, gut ischemia-reperfusion, leukocyte activation and, 345
Arginine
electronic searches of JPEN archives on, 218 (Editorial)
fatty acids interaction with, S75
sepsis and, S70 Endotoxins, Kupffer cells role after major liver surgery and, 48
Arsenic species, in parenteral nutrition solutions, 1 Energy expenditure. See also Resting energy expenditure
Artificial intelligence, urea nitrogen appearance prediction for critically ill comparison of two measuring systems of, 212
patients, 429 prediction methods for critically ill patients, 59 (Letter)
Ascorbic acid, stability, multilayered PN bags and, 125 Enteral nutrition (EN)
in adults with Crohn’s disease, S166
anti-inflammatory effects of, S134
in childhood Crohn’s disease, $151
sariatric surgery, PN effect on nutrition status after, 445 in childhood Crohn’s disease, immunosuppressive therapy and, $160
Bioactive molecules in childhood Crohn’s disease, microflora and, S173
in immune-enhancing diets, S49 Crohn’s disease and, $108
in inflammatory bowel disease, S179 early, metabolic and clinical consequences of, 108
Bioimpedance, body mass index in anorexia nervosa and, 148 feeding-tube properties and gastric residual volume in, 192
3irth weight, maternal hyperemesis gravidarum and, 93, 134 (Editorial) gut-associated lymphoid tissue and T lymphocytes numbers in, 56
Body composition, PN impact on patients with acute pancreatitis and, 65 gut IL-4 and IL-10 expression and, 44
Body mass index, bioimpedance and anthropometry estimates of body com- hospitalized type 2 diabetics, evaluation of 2 formulas for, 21
partments in anorexia nervosa and, 148 inflammation control with TGF-f formulas for, S126
30dy weight, long-term enteral nutrition and, 198 inflammatory bowel disease and, S107, S184
Breast milk feedings, lipogenesis during breast total PN versus, 81 long-term, body weight and, 198
3urns, severe, diarrhea in children with, 8 long-term, copper deficiency and, 360
nutrition support protocol in adult ICU and targets for, 74
oxidation of fatty acids and lipids during storage of formula for, 204
w-3 fatty acids in, after esophageal cancer surgery, 141
Cachexia, leptin production in gastric cancer and, 229 Epidermal growth factor (EGF)
Calorimetry, indirect intestinal growth induced by glucagon-like peptide 2 and, 248
comparison of two systems for, 212 protein phosphorylation and, 322
resting metabolic rate prediction methods for critically ill patients and, 59 Esophageal cancer, w-3 fatty acids in EN after surgery for, 141
(Letter)
Cancer of head and neck, long-term enteral nutrition, body weight and, 198
Carbon dioxide, hypercaloric feeding and production in patients with mechan-
ical ventilation of, 380 Fasting, preoperative, 298
Caretakers, of children on home enteral nutrition, well-being of, 413 Fatty acids
Catabolism, in critically ill patients, using artificial intelligence to predict, 429 arginine interaction with, S75
Catheters oxidation during enteral formula storage, 204
central venous, PN as risk factor for infections related to, 367 Fatty acids, w-3
line sepsis in home parenteral nutrition, 408, 456 (Editorial) in EN after esophageal cancer surgery, 141
peripherally inserted central, 374 preoperative oral supplementation with, 236
peripherally inserted central venous, home PN access using, 425 5-Fluorouracil, GALT cell number, mucosal IgA levels and infusion of, 395
Celiac disease, after pancreaticoduodenectomy, 270 Food and Drug Administration, US, rofecoxib approval, marketing, litigation
Cell proliferation, of intestinal cells after small-bowe! resection, leptin and, 30 and, 136 (Editorial)
Children
critically ill, nasojejunal feeding tube placement in, 420
with Crohn’s disease, and EN as primary therapy for, $151 Gastric cancer, hypoleptinemia and, 229
with Crohn’s disease, and resting energy expenditure in parenterally-fed, 102 Gastric residual volume, feeding-tube properties and, 192
with Crohn’s disease, EN and growth of, $134 Gastrostomy tubes. See also Tube feeding
with Crohn’s disease, EN and microflora in, $173 pH and temperature roles in deterioration of, 388
with Crohn’s disease, immunosuppressive therapy and EN for, S160 Gene expression, individual nutrients and, 392 (Editorial)
on home EN, caretaker well-being and, 413 Genetics, immunopathogenesis of Crohn’s disease and, $118
mortality reduction after nutrition support team implemented in PICU, 176 Glucagon-like peptide 2 (GLP-2)
severely burned, diarrhea in, 8 intestinal adaptation after small-bowel resection and, 97
with short bowel syndrome, long-term follow-up of, 186 intestinal growth induced by epidermal growth factor and, 248
Cholestasis, PN—associated, in neonates, taurine and, 337
Glucose
Colon, amino acids and protein synthesis in, EN for type 2 diabetics and control of, 21
Compounding pumps, extending use of transfer sets on, 118 management protocol in trauma ICU, 353
Copper, long-term EN and deficiency of, 360 metabolism and glycemia in sepsis during hyperinsulinemic clamp, 171
Critically ill patients Glutamine
EN for, reduced costs and morbidity in, 455 (Letter), S62 electronic searches of JPEN archives on, 218 (Editorial)
multiple trauma, artificial intelligence and catabolism in, 429 PN and, 262
multiple trauma, treatment of acute hypocalcemia in, 436 use in cecal ligation and puncture-induced sepsis, diaphragm muscle
nasojejunal feeding tube placement in children, 420 function and, 36
resting metabolic rate equation estimates for, 59 (Letter) Glycemia, and glucose metabolism in sepsis during hyperinsulinemic clamp, 171
specialized nutritional formulas for, S92 Growth, in children with Crohn’s disease, EN and, $134, S151
Crohn’s disease. See also Inflammatory bowel disease Growth hormone (GH), protein phosphorylation and, 322
adults with, enteral nutrition for, S166 Gut-associated lymphoid tissue (GALT)
children with, and EN as primary therapy for, S151 EN and T lymphocyte numbers in, 56
children with, EN and growth of, $134 5-fluorouracil infusion and cell number of, 395
children with, EN and microflora in, $173
children with, immunosuppressive therapy and EN for, S160
EN in management of, S108
immunopathogenesis of, $118 Health care, universal, 311 (Editorial)
resting energy expenditure in parenterally-fed children with, 102 Health care costs
159
460 SUBJECT AND AUTHOR INDEX TO VOLUME 29 Vol. 29, No. 6
of home ersus hospital yased PN, 266 Leptin, gastric cancer and change in, 229
ost-benefit analysis of preoperative immunonutrition, S57 Leptin-deficient obese mice impaired intestinal cell proliferation and cell
ly ill ICU patients, patient morbidity and, 455 death in, 30
Le 2 Leukocyte activation, gut ischemia-reperfusion, dietary restriction and, 345
) ¢ sus hospital-based nutrition support after surgery, S96 Lipids
peripher inserted central catheters and, 374 EN for type 2 diabetics and control of, 21
spec ed nutritional formulas and, S81 oxidation during enteral formula storage, 204
Hemoy c stem cell transplantation, PN and, 241 Liver
Hepatocytes, high-fiber diet after partial hepatectomy and apoptosiosf , 401 high fiber diet after partial hepatectomy and regeneration of, 401
hepatocyte apoptosis, liver regeneration after partial hepatec- Kupffer cells role after major surgery of, 48
my and, 401 nutritional {f actors and per? gene expression in, 157
H transgenic rats, milk cas¢ ased diet with TGF-B and inflamma-
Home er well-being and, 413
Home paret Macronutrients, in inflammatory bowel disease, $179
Magnet-tracking system, for nasogastric tube placement verification, 305
entr Malnutrition
( n rsus, 266
metabolic and clinical consequences of early enteral nutrition and, 108
fe for adults and, 16 severe obesity and, A.S.P.E.N.’s role in, 288
MedGem, energy expenditure measurements by DeltaTrac versus, 212
socioeconomic effects on, 456 (Ed
Medical issues
irinary oxalate excretion and vitamin C dose in, 454 (Letter
for caretakers of children on home enteral nutrition, 413
Hyper ric feeding. See also Nutrition support
Medically uninsured, health care for, 311 (Editorial)
mechanical ventilation and, 380
Hypere sis vidarum, maternal, neonatal birth weight and birth outcomes Microflora, EN in childhood Crohn’s disease and, $173
with, 9 Editorial Mortality
Hyperinsu mic clamp, glycemia and glucose metabolism in sepsis during, nutrition support in PICU and, 176
171 Mucosal addressin adhesion molecule-1 (MAdCAM-1), EN and preservation in
Hype r treatment in critic: ultiple-trauma patients, gut of IL-4 and IL-10, 44
136
Hypoleptine 4, gastric cancer and, 229
Nasogastric tubes, placement verification with magnet-tracking system, 305
Normoglycemic man: ment protocol, in trauma ICU, 353
lt resp Nutrients, gene expression and, 392 (Editorial
Nutrition support. See a/so Hypercaloric feeding
rginil teraction with fatty acids and diets enhancingS7,5
economic study of post-surgical home versus hospital-based, S96
n Croft s disease, S118
fection, nutrition support d, S5 EN targets and protocol in adult ICU for, 74
trition support and, 549 gene expression and, 392 (Editorial
Imi Du A (IgA improving outcomes with, S49
5-fluorouracil infusion and mucosal levels of, 395 mortality reduction in PICU and, 176
per2 gene expression in suprachiasmatic nucleus and liver and, 157
mmunonutrition, preoperative, cost-benefit analysis of, S57
1UnOsuppressive therapy, in childhood Crohn’s disease, EN and, $160 preoperative oral « 3 fatty acids, 236
preventing infectious complications with, S53
pursuit of optimal, 272
specialized formulas for, cost-effectiveness of, S81
specialized formulas for critical care and surgery, S92
Inf
I ind, 93, 134
Obesity
nt morbid, PN effect on nutrition status after bariatric surgery for, 445
ke growth factors in, 87 resting metabolic rate prediction methods for critically ill patients and, 59
Infe
Letter
ernetirtrar all ve veernnolooe uuss in. ccaaStt7hh0ee tteerr--rerlealtaetde,d , hPoNm e and,P N 367a nd, 425, 456 (Editorial Orotas3te1ev5,e rei,n crAes. S.P.E.inN J jejurnoalle imnu, co28s8a growth after small-bowel resection and,
lications from, nutrition inte entions and, 59 urinery, vitamin C dose in home PN and, 454 (Letter
with TGF-8 formulas, $126
control with TGF-£ formul
and roo eduction of, PeleSe1 34 Pancreaticoduodenectomy, celiac disease after, 270
Kupffer cells role after n Pancreatitis
Inflammatory bowel disease. See also ( s disease acute, PN and body composition of patients with, 65
enteral 1 ition in, S107, S184 chronic, jejunal long-term feeding in, 12
cro rients and bioactive molecules in, $179 Parenteral nutrition (PN). See also Total parenteral nutrition
Ins e growth factors, postnatal weight gain in premature infants and after bariatric surgery, nutrition status and, 445
serum levels of. 87 alanyl glutamine in, 262
Intensive care units ICU arsenic species in solutions for, 1
enter tion and reduced costs, patient morbidity in A.S.P.E.N. Safe Practices for, 61 (Editorial)
S62 bag wall material and ascorbic acid stability in, 125
entera! nutrition targets and nutrition support protocol in, 74 body composition of patients with acute pancreatitis and, 65
pediatric, mortality reduction afer nutrition support team implemented central venous catheter-related infection and, 367
il 176 economic analysis of home versus hospital-based, 266
rauma, normogiv} cemic Management t pr“ontto co : 1, 2V OD EGF, GLP-2 interactions in intestine and, 248
Interleukin-4, EN and preservation extending use of transfer sets on compounding pumps for, 118
Interleukin-10, EN ind preservation 1 hemopoietic stem cell transplantation and, 241
neonatal cholestasis and taurine effects with, 337
Ir te sting >
EGF d GLP-2 in ractions in, 248 resting energy expenditure in children with Crohn's di “ase and, 102
GLP-2 nd adaptation after small-bowel resection by, 97 urticaria associated with, 451
ischemia-repertusion, of gut dietary restriction, leukocyte activation and, Patient safety, 61 (Editorial)
45 Patient safety, rofecoxib approval by FDA, marketing, litigation and, 136
Editorial
Per2, nutritional factors and gene expression in suprachiasmatic nucleus and
liver by, 157
Jejunal feeding, long-term, chronic pancreatitis and, 12
Percutaneous endoscopic gastrostomy (PEG) tubes, placement safety with
ventriculoperitoneal shunts, 442
pH, gastrostomy tube deterioration and, 388
Kupffer cells, role after major liver surgery, 48 Poverty, health care and, 311 (Editorial)
November—December 2005 SUBJECT AND AUTHOR INDEX TO VOLUME 29
Preoperative nutrition late regeneration of infarcted mucosa after, 131
immunonutrition for, cost-benefit analysis of, S57 leptin effects on intestinal cell proliferation and cell death after, 30
oral w-3 fatty acids, 236 Socioeconomic factors
role of fasting in, 298 home PN and, 456 (Editorial)
Presidential Address, Severe Obesity: A Growing Health Concern A.S.P.E.N. line sepsis in home parenteral nutrition and, 408
Should Not Ignore, 272 Stem cell transplantation, hemopoietic, PN and, 241
Protein phosphorylation, epidermal growth factor and/or growth hormone and, Suprachiasmatic nucleus, nutritional factors and per2 gene expression in, 157
322 Surgery
Protein synthesis home versus hospital-based nutrition support after, economic study of, S96
postoperatively in colon, amino acids and, 255 specialized nutritional formulas for patients undergoing, S92
severe undernutrition subsequent refeeding and, 221
Psychosocial issues, for caretakers of children on home enteral nutrition, 413
Taurine, PN—associated neonatal cholestasis and, 337
Temperature, gastrostomy tube deterioration and, 388
T lymphocytes, numbers in gut-associated lymphoid tissue, EN and, 56
Quality of life, for adult home parenteral nutrition patients, 162 Total parenteral nutrition (TPN). See also Parenteral nutrition
lipogenesis during breast milk feedings versus, 81
Toxic potential, arsenic species in PN solutions and, 1
Refeeding, protein synthesis, whole-body metabolism after severe undernutri- Transforming growth factor 6 formulas
tion and, 221 inflammation control in HLA-B27 transgenic rats and,
Refeeding syndrome, metabolic and clinical consequences of early enteral inflammation control with, $126
nutrition and, 108 Tube feeding. See also Gastrostomy tubes
Resting energy expenditure (REE). See also Energy expenditure feeding-tube properties and residual volume measurements in, 192
severe undernutrition subsequent refeeding and, 221 nasogastric, placement verification with magnet-tracking system, 305
Resting metabolic rate, prediction methods for critically ill patients, 59 (Letter) nasojejunal placement, in critically ill children, 420
Retrospective studies, chronic pancreatitis and long-term jejunal feeding, 12 PEG tube placement with ventriculoperitoneal shunts, 442
Rhoads Lecture
A 45-Year Obsession and Passionate Pursuit of Optimal Nutrition Sup-
port: Puppies, Pediatrics, Surgery, Geriatrics, Home TPN, A.S.P.E.N., Ultrasound, bedside, peripherally inserted central catheters and, 374
Et Cetera, 272 Undernutrition, severe, protein synthesis, whole-body metabolism and, 221
Rofecoxib, FDA approval, marketing, litigation and, 136 (Editorial) Uracil, increases in jejunal mucosa growth after small-bowel resection and,
315
Urea nitrogen appearance, using artificial intelligence in critically patients to
predict, 429
Sepsis. See also Infections Urticaria
arginine role in, S70 PN-associated with, 451
extending use of transfer sets on compounding pumps and, 118
glycemia and glucose metabolism during hyperinsulinemic clamp with,
171 Vars Award Recipient: Dietary Supplementation with Orotate and Uracil
in home parenteral nutrition catheters, 408 Increases Adaptive Growth of Jejunal Mucosa after Massive Small Bowel
Sepsis, cecal ligation and puncture-induced, alanyl-glutamine effect on dia- Resection in Rats, 315
phragm muscle function in, 36 Ventilation, mechanical, hypercaloric feeding and, 380
Short-bowel syndrome Ventriculoperitoneal shunts, safety of PEG tube placement after, 442
children with, long-term follow-up of, 186 Vitamin C, urinary oxalate excretion in home PN and dose of, 454 (Letter)
late regeneration of infarcted mucosa after small-bowel resection and, 131
Small-bowel resection
glucagon-like peptide 2 and intestinal adaptation after, 97 Weight gain, postnatal, and serum IGF-like growth factors in premature
increases in jejunal mucosa growth with orotate and uracil after, 315 infants, 87
SUBJECT AND AUTHOR INDEX TO VOLUME 29 Vol. 29, No. 6
AUTHOR INDEX Cresci G, S50, S81, S92 Haaker R, 236 Marks T, 221 Reese SR, 44
Croce MA, 429, 436 Hameed SM, 74 Marshall JK, 266 Richards H, 102
Croft NM, $134 Hara E, 345, 395 Marteau P, S166 Rider DL, 388
Abbott SPAI-97—004 Study Culebras JM, 262 Harbrecht BG, S75 Martindale R, S50, S81 Rider JA, 388
Cooperative Group, 21 Hart] WH, 255 Martinez MI, 186 Rittler P, 255
Agusto de Aguiar Carrazedo Harvey-Banchik L, 134 Martinez Olmos MA, 445 Robinson MK, 374
Taddei J, 176 Dahlgren J, 337 Hashiguchi Y, 56 Martinez Vasquez MJ, 445 Rocha FG, 97
Aiko S, 141 Daveau M, 48 Head G, 118 Martinka GP, 108 Roorda AK, 388
Alexander KH, 436 Davidson NO, 270 Herndon DN, 8 Maruri Chimeno I, 445 Roscher AA, 255
Allard J, 408, 454 Davis AT, 93 Heuschkel R, $160 Marx A, 12 Rosenblatt JI, 8
Ando T, 360 de Azevedo MJ, 367 Hiraide H, 56, 345, 395 Mason DL, 429 Rosin D, 131
Anthony PS, $107 de Carvalho LM, 1 Hirsch] RB, 337 Masson §, 48 Rounds J, 97
Aouthmany MM, 337 Del Buono B, 186 Hise M, 359 Matta B, S75 Rubin A, 413
Archer KA, 108 DeLegge MH, 12, 425 Hofman Z, 298 Mauro M, 305 Rufian-Henares JA, 204
AAsrhmlsetyr onSgW, D9,7 266, 305 de Martino M, $173 Homann H-H, 236 May A, 353 Rusavy Z, 171
Demmelmair H, 255 Hsu W-Y, 87 McCollom RA, 108
Atici S, 36 DeRusso PA, 337 Huang Q, 229 McDoniel K, 270 Saalwachter Schulman A, 442
AAAAvvyzilaasalmsnoaa nr D,TAN ,, E3,611 53713 22 DDDDiieeaasuszst zu yJM CNJGErM.,P,, , 31S5 S9376 0 HIIunklaerdsaaej aS M,A B,4o 4b o4 20M T, 445 MMMMeiieliktljihee err Hn ,yRC ,, 1 N5347A58 ,3 192 SSSSaaaacnqnkzudsi-e PrasGOro,,i n s 34 5018IA, R, , 42$511 43 4
Bannister L, 102 DDiikcsk erJs, on4 8, R2N9,8 429, 436 IIsrheitdoan -JNo,n e1s5 7 C, 59 MMiilnlairnde r GD,, 442594, 436 SSaaxw yeHrC , R3G2,2 442
BBaanrskasld alVe, SE7M5 Jr., 320 DDii p PaNs,c ol2i2 1 L, 148 IIttoo YH,, 39670 MMoocgheinzsuekni KHM, , 56,3 743 45, 395 SScchhiaetftenre r B, MA2,55 198
Bar-Zakai B, 131 DiSabatino A, $118 Iwanaga H, 157 Monden M, 157 Schiffrin EJ, $141
Bassilian S, 81 Doig CJ, 74 Moore N, 425 Schlageter V, 305
Baun M, 454 do Nascimento PC, 1 Morales Gorria MJ, 445 Scolapio JS, 451
Baxter YC, S96 Donnet A, $141 Jackson C, 102 Morellit L, S173 Scott B, 198
Beattie RM, $151 Doruk N, 36 Jacobs DO, 374 Morgan LG, 436 Scotté M, 48
Becker E, 1 Dray X, S166 Jacobs R, 255 Moriya T, 345 Senkal M, 236
Beghetto MG, 367 Dudrick SJ, 272 Jauch K-W, 255 Morris J Jr., 353 Shabtai M, 131
Bell C, 81 Dupertuis YM, 125 Moses J, S62 Shike M, 198
Bercik P, 305 Dupont W, 353 Shikora SA, 288
3erlanga-Acosta J, 248 Duxbury M, 97 Nabeshima T, 360 Shimanouchi M, 141
Bierling S, 93 Jorguera F, 262 Nagai K, 157 Shinto E, 56, 345
Bilgin E, 36 El Yousfi M, $141 Nagayoshi H, 56, 345, 395 Shulman RJ, 337
BBBolleoulomem n sS ,S RP,$G 1,4 214 84 8, 298 EEEnnvrnaisno sn eR, M EE,4B0 ,8 31451 3 KKKeihlealliyyk iJnDM G,, M ,34 05 413 1 NNNioajhkv ealJyd-atH m, aR J3,0 M,4 8, 15279 8 SSSikkroootpen ni cA,kM i P24CA1,B , 428 41
Boffo G, 148 Kien L, 8 Novak I, 171 Smith JS, 59
Bohrer D, 1 Kitchen PA, 248 Nuetzel G, 192 Spencer AU, 337
sorak G, 425 Fairholm L, 454 Klein S, 270 Sramek V, 171
Bouritius H, 298 farber MS, S62 Kobayashi M, 157 Stanga Z, 12
3raga M, S57 ‘arivar RS, 97 Kohler S, 374 Obled C, $141 Stechmiller JK, 343
B33rrraeaunnislnlooénn DRR,,, S2S1174251 FFFaaaturhroieo kiM M,, A,1 $21544 515 KKKooollrenat rzzkMyo,k SBE6,,2 225451 OOOickshahodiaa KJ,KB ,, 1 51S75 775 SSSttteeehwwlaaerr tt P,CJ ,L2 ,3 169 221 2
Brogan A, S81 Fell JME, S126 Krauss J, S81 Okamoto K, 56 Stone CD, 270
Brown M, 337 Ferrari S, $173 Krick M, 255 O'Keefe SJ, 221 Strasberg SM, 270
Brown MB, 337 Ferrone M, 451 Kucera P, 305 Oliver D, 192 Strickland A, S81
Brown P, 198 FitzGerald AJ, 248 Kudsk KA, 44 Omata J, 395 Strouse PJ, 337
Brown RO, 429, 436 Flesher ME, 108 Oral U, 36 Sugiura Y, 141
Bruno de Carvalho W, 176 Ortiz de Urbina JJ, 262 Swartz-Basile DA, 30
Buyukakilli B, 36 Forbes A, 248 Lacigova S, 171 Oiero Martinez I, 445 Syres KM, S75
Forbes R, 353 Lai H-S, 401 Ozdas A, 353
Fortin M, 102
zee P-H, 401
Cabre E, $179 Frankenfield D, 59 Takiguchi S, 157
Callanan M, 221 Fujiwara Y, 157 LLeeee SW,N P81, 81 Paauw JD, 93 Taner L, 36
Callegari ML, $173 Fukatsu K, 56, 345, 395 ite HP, 176 Parada Gonzalez P, 445 Tappenden KA, 335
Caregaro L, 148 on-Sanz M, 21 Pedrosa E, $179 Teitelbaum DH, 337
Casal Nunez JE, 445 Pena Gonzalez E, 445 Teixeira L, 367
Casimiro C, 21 Gadowsky SL, 266 Leslie BD, 108 Pencharz P, 102 Tesinsky P, 171
Cauthern AD, 436 Garcia-Luna PP, 21 ai J-S, 229 Perez A, 97 Thakkar K, 8
Cavicchi MC, $173 Garcia-Villanova B, 204 ii N, 229 Pérez NB, 186 Thomas NJ, 420
Cecconello I, S96 Garg M, 81 Lieske JC, 454 Phipps LM, 420 Thomlinson B, 413
CCCChhhhaeaatnnnu gdr r Pe-ARs,N, e, g4a04480r0 18a m MD, 65 GGGGaheisaansnttuoeoltinlt i MLMA,LA ,,, 4 4S2 5$4718 7 9 LLLiiiinnon nseeCWti--tsHiHe, ,n P3,J8 4,00$ 1 1 27336 PPPPiiiictnctcah o aliHrd Ade, A ,Cl a3, 0 1 V418e2 g5a L, 454 TTTToirriuaajanci yl lJLo,,T F33,K12 ,52 313374
Chen W-J, 401 Giger U, 12 Au B-Z, 229 Planas M, 21 Tsai F-A, 87
CChhii ldCs- Y,A , 8276 6 GGiilnldhearm BRR,A , 42405 1 LLlo anHo-sC , A,8 7,3 373 80 PPllaaynfko rdL D,R J6,5 248 TTssaaio LL--JY,, 38870
Chung K, 118 Gomez-Candela C, 21 wuiking YC, S70 Poeze M, S70 Tsuwano S, 141
Cinel I, 36 Gonzalez HF, 186 Pozzi E, $173 Tunon MJ, 262
Cinel L, 36 Gonzalez-Gallego J, 262 Macdonald IA, 171 Prakash C, 270
Clouse RE, 192 Goodlad RA, 248 MacDonald TT, $118 Prins HA, 48 Ueno C, 56, 345, 395
Codognotto M, 148 Goody CN, 212 Mackenzie SL, 74
Collier B, 353 Gordon JN, $118 Maculevicius J, S96 Quesada O, 198
Combaret L, $141 Griffiths AM, S108 Maehara T, 141 van Hoorn DEC, 298
Conroy BF, 388 Groner JI, 337 Maeshima Y, 345, 395 van Leeuwen PAM, 48, 298
Cook CR, 93 Grudinskas GF, 3 4 Mager D, 102 Ramsanahie AP, 97 van Norren K, 298
Cooney RN, 59 Gu LH, 315 Makarenkova V, S75 Ramsay G, S70 Van Way CW, III, 61, 136,
Cormier K, 102 Guerra-Hernandez E, 204 Malpeli A, 186 Ramseyer S, 125 218, 311, 392, 456
Cotteleng B, S96 Gurgueira GL, 176 Mandi N, 248 Rawlinson J, 305 Varnholt H, 97
( ox J, 337 Guy J, 353 Mane J, S179 Raykher A, 198 Victorino J, 367
November—December 2005 SUBJECT AND AUTHOR INDEX TO VOLUME 29
Villares C, 262 Whitmore BL, 74 Wong H, 97 Zaloga GP, S49
Viteri FE, 186 Whittaker S, 408 Wu H-C, 401 Zhang X, 229
Willis HJ, 198 Ziegler TR, 315
Waitzberg DL, S96 Windsor JA, 65 Yano M, 157 Zinner MJ, 97
Walters JRF, 248 Winkler MF, 162 Yasuda T, 157 Zmora O, 131
Weber MD, 420 Winter TA, 221 Yoshizumi Y, 141 Zygun DA, 74
Whang EE, 97 Wolfram G, 236 Yu S, 337